Mammalian target of rapamycin inhibitor (mTOR-I)/proliferation signal inhibitors (PSI) including sirolimus (SRL) and everolimus (EVL) represent a new class of drugs increasingly used in solid organ transplantation as alternatives to calcineurin inhibitors for patients with renal dysfunction, transplant coronary arterial vasculopathy (TCAV) or malignancy \[[@SFU001C1]\]. Though generally well tolerated, the use of mTOR-I/PSI is associated with many side effects, which may account for the 20--40% drop-out rate for SRL/EVL in clinical Phase III trials. Some side effects are easily manageable, whereas others lead to drug discontinuation \[[@SFU001C2]\]. Oedema induced by mTOR-1/PSI takes different clinical forms ranging from the banal lymphocele to the dramatic angio-oedema (AE). This article reviews the incidence (Table [1](#SFU001TB1){ref-type="table"}) \[[@SFU001C3]--[@SFU001C13]\], clinical presentation (Table [2](#SFU001TB2){ref-type="table"}) \[[@SFU001C14]--[@SFU001C24]\] and mechanisms of oedema within the clinical experience of mTOR-I/PSI in solid organ transplantation. Table 1.Incidence of oedema induced by EVL in solid organ transplantationAuthorStudyOrgan transplantFollow-up (months)EVL mean level and/or mean dosageOedema incidenceEVLControlLehmkuhl *et al*. \[[@SFU001C3]\]Multicentre open-label study RAD2411Heart transplant124.1 ± 1.8 ng/mLEVL, 91 patientsPeripheral oedema, 39.6%Pericardial effusion, 35.3%Pleural effusion, 24.2%MMF, 83 patientsPeripheral oedema, 34.9%Pericardial effusion, 25.3%Pleural effusion, 13.3%Gullestad *et al.* \[[@SFU001C4]\]Multicentre randomized trialHeart (*n*=190) and lung (*n*=92) transplant123--8 ng/mLEVL+, 140 (29.3%)EVL−, 142 (8.5%)Gullestad *et al.* \[[@SFU001C5]\]Multicentre randomized trialHeart (*n*=190) and lung (*n*=92) transplant244.5 ± 1.4 ng/mLEVL+, 103 (8.3%)EVL−, 119 (8.7%)Roman *et al.* \[[@SFU001C6]\]Retrospective, EVERODATA lung substudyLung transplant126.4 ± 2.8 ng/mL5/65 (7.7%De Simone *et al.* \[[@SFU001C7]\]Randomized controlled trail, H2304 study groupLiver transplant126--10 ng/mLEVL+ reduced TAK 43/245 (17.6%)TAC elimination, 42/231 (18.3%)TAC control, 26/243 (10.8%)Alegre *et al.* \[[@SFU001C8]\]RetrospectiveLiver transplant485.5 ± 2.2 ng/mLEVL overall, 13/57 (28.8%)EVL monotherapy,5/24 (20.8%)EVL combination8/30 (24.2%)Saliba *et al.* \[[@SFU001C9]\]Randomized controlled trail, H2304 study groupLiver transplant24AEEVL+ reduced TAC, 6/245 (2.4%)TAC elimination, 4/231 (1.7%)TAC control, 5/243 (2.1%)AscitesEVL+ reduced TAC, 11/245 (4.5%)TAC elimination, 14/231 (6.1%)TAC control, 11/243 (4.5%)Peripheral oedemaEVL+ reduced TAC, 55/245 (22.4%)TAC elimination, 45/231 (19.7%)TAC control, 36/243 (14.9%)Pleural effusionEVL+ reduced TAC, 15/245 (6.1%)TAC elimination, 7/231 (3.1%)TAC control, 13/243 (5.4%)Lorber *et al.* \[[@SFU001C10]\]Randomized, multicentre Phase III studyKidney transplant36EVL 1.5 mg/d101/193 (52.3%)MMF, 82/196 (41.8%)EVL 3 mg/d92/191 (47.4%)MMF, 82/196 (41.8%)Cotovio *et al.* \[[@SFU001C11]\]Retrospective register-based studyKidney transplant65.9 ± 2.6 ng/mL8 (5.3%)--Shihab *et al.* \[[@SFU001C12]\]Randomized controlled trialKidney transplant12\<3 ng/mL18/29 (62.1%)--3--6 ng/mL94/212 (44.3%)--6--8 ng/mL55/105 (52.4%)--≥8 ng/mL17/26 (65.4%)--Takahashi *et al.* \[[@SFU001C13]\]Multicentre, open-label randomized studyKidney transplant121.5 mg/dayEVL, 20/61 (32.8%)MMF, 8/61 (13.1%)[^1] Table 2.Case reports of oedema induced by mTOR-I/PSIs: clinical featuresReferenceOrgan transplantmTOR-I/PSIOedemaFollow-upDosageLevelOnsetClinical featuresAction\[[@SFU001C14]\]HeartEVL, 0.75 mg/day8 ng/mL1 monthHand and forearmsEVL dose reductionPartial resolutionEVL, 0.5 mg/day5 ng/mL1 monthHand and forearmsPartial resolutionSwitch to SRL, 1 mg/day10 ng/mLFew daysIncrease in the oedemaStopComplete resolution 2 months after\[[@SFU001C15]\]HeartEVL,NA36 monthsBilateral chylothoraxSwitch EVL to MMFComplete resolution within 8 monthsReintroduction of EVL (TCAV progression)NA4 monthsPleural effusionEVL discontinuationComplete resolution\[[@SFU001C16]\]KidneyEVL, 0.5--1 mg/day\>3 ng/mL12 monthsFeet oedemaNoProgression to upper extremities and left breastEVL discontinuationComplete resolution within 3 months\[[@SFU001C17]\]KidneyEVL, 1.5 mg/day (6 patients)3--8 ng/mL2--41 daysAEHospitalizationIV prednisone and clemastinAcetyl-salicylic acid stoppedFive patients were free from recurrence despite EVL maintenance. One patient experienced two recurrent episodes before under EVL, stopped\[[@SFU001C18]\]KidneySRL, dosage NANA3 monthsMild oedema on both legs, LUE and left breast, recurrent lymphangitisSRL discontinuationComplete resolution within few monthsKidneySRL, dosage NANA6 monthsMild oedema on both legs and redness of RUE and right breast,SRL discontinuationPartial resolution, 60--70% within few monthsKidneySRL, dosage NANA4 monthsOedema both legs, nephrotic syndromeSRL discontinuationPartial resolution, 80--90% within few weeks\[[@SFU001C19]\]KidneySRL, 9.5 mg/day26.3 ng/mL36 monthsSevere oedema and redness of LUE and left breast,Reduction of SRL dosage (trough levels of 5--10 ng/mL)Partial resolution, 60--70%KidneySRL, 2 mg/day5--10 ng/mL6 monthsSevere oedema of RUE and right breast, functioning access RUESRL withdrawal, conversion to CSAPartial resolution, 70--80%\[[@SFU001C20]\]KidneySRL, 3 mg/day10--18 ng/mL30 monthsLymphoedema of the left upper limbSRL withdrawalSignificant improvementKidneySRL, 3 mg/day10--15 ng/mL30 monthsLymphoedema of the left lower limbSRL withdrawalSignificant improvement within few monthsKidneySRL, 3 mg/day10--18 ng/mL24 monthsLymphoedema of the left lower limbSRL withdrawalSignificant improvement within few months\[[@SFU001C21]\]KidneySRL, 5 mg/day12--20 ng/mL3 monthsGeneralized lymphoedemaSRL withdrawalComplete resolution 3 months after\[[@SFU001C22]\]KidneySRL, 19 mg/day10.3 ng/mL1 monthAESteroids + diphenhydramine and SRL withdrawalComplete resolution 2 days afterKidneySRL reintroduction, 20 mg/day3.1 ng/mL1 dayAESteroids + diphenhydramine and SRL withdrawalComplete resolution 2 days afterKidneySRL, 8 mg/day19.4 ng/mL14 daysAESteroids + diphenhydramine and SRL withdrawalComplete resolution 2 days after. However, the patient inadvertently received two more daily 4 mg doses of SRL, and AE recurred. SRL was then switched to cyclosporin A, and there has been no recurrence in the subsequent 11 months\[[@SFU001C23]\]KidneySRL, 1--20 mg/day (5 patients)5--19 ng/mL1--5 monthsEyelid oedema of variable severityDose reduction, temporary or definitive SRL discontinuationComplete resolution\[[@SFU001C24]\]HeartSRL, 2 mg/day2.5 ng/mL12 monthsFacial and right arm oedemaSRL withdrawalComplete resolution 6 weeks after[^2]

Lymphocele {#s2}
==========

Lymphocele is a well-known complication after kidney transplantation. It occurs among 0.6--22% of symptomatic patients being treated with cyclosporine (CsA)-based immunosuppression \[[@SFU001C25]--[@SFU001C31]\] and 49% of asymptomatic cases detected by ultrasonography during a 2- to 11-year follow-up \[[@SFU001C32]\]. mTOR-I/PSI are associated with an increased incidence of mild or moderate lymphocele. In clinical studies, the rates of lymphocele in renal transplant patients receiving a 6-month treatment with EVL 1.5--3.0 mg/day, or SRL 2.0--5.0 mg/day were 6.4--15.2 \[[@SFU001C33]\] and 12--13% \[[@SFU001C34]\], respectively. Post-marketing experience with SRL has demonstrated an increased incidence of lymphoceles. Factors predisposing to lymphocele formation include drainage from open lymphatics divided during surgery to dissect the host iliac vessels \[[@SFU001C29], [@SFU001C35]\], injured lymph channels in the donor kidney hilum vessels \[[@SFU001C31], [@SFU001C36]\], acute allograft rejection episode \[[@SFU001C26], [@SFU001C37], [@SFU001C38]\], acute tubular necrosis \[[@SFU001C26]\], transplant kidney biopsy \[[@SFU001C30]\], retransplantation \[[@SFU001C39]\] and adult polycystic kidney disease as the original renal disease \[[@SFU001C40]\]. Clinical experience shows that mild lymphocele can resolve itself, while moderate lymphocele usually responds to povidine-iodine \[[@SFU001C41]\]. Although some patients who receive mTOR-1/PSI may develop early massive lymphocele that requires surgery, mTOR-1/PSI dose reduction or complete withdrawal is not necessary. Surgery for lymphocele is not common \[[@SFU001C42]\].

Eyelid oedema {#s3}
=============

Eyelid swelling is often the herald of significant systemic or periorbital disease. The aetiological list is extensive. Many medications---topical, oral and parenteral---are well recognized to create eyelid swelling through generalized fluid retention, AE, urticaria or topical blepharoconjunctivitis. mTOR-1/PSI-related eyelid oedema in kidney transplant recipients was described in a few case reports of SRL- \[[@SFU001C18], [@SFU001C23]\] and EVL-based \[[@SFU001C43]\] treatments. Development of eyelid oedema was gradual, occurring over 1--5 months after starting mTOR-I/PSI. The oedema may be mild and easily managed with low-dose furosemide and reduction of SRL dose was not warranted. In some patients, discontinuation of mTOR-I/PSI was followed by delayed resolution of the swelling, with full recovery taking as long as months. The underlying mechanism is unknown.

Oedema and lymphoedema {#s4}
======================

Leg swelling is an extremely frequent symptom with a broad variety of largely differing causes. The most important mechanisms behind the symptom include venous and lymphatic pathology, volume overload, increased capillary permeability and lowered oncotic pressure. Therefore, the most frequent diseases associated with leg swelling are deep vein thrombosis and chronic venous insufficiency, primary or secondary lymphoedema, cardiac failure, hypoproteinaemia, idiopathic cyclic oedema and drug-induced oedema. Lymphoedema may be primary (congenital lymphatic abnormality) or secondary, frequently related to cancer treatment. Other causes of secondary lymphoedema include obstruction by tumour, infection (filariasis), recurrent cellulitis and connective tissue disease. A less-common form of oedema is lymphoedema, which causes an abnormality in the lymphatic system. The most common cause is interruption of the axillary lymphatic system by surgery and/or radiation therapy in women with breast cancer.

Unilateral or bilateral peripheral oedema/lymphoedema is common following the initiation of mTOR-I/PSI use \[[@SFU001C24], [@SFU001C43]\] and frequently sufficiently severe enough to require medication discontinuation. However, it may be less frequent with EVL with a retrospective series reporting 4- to 5-fold less oedema when compared with matched SRL-treated patients (14 versus 64%), respectively \[[@SFU001C14]\]. It has been mentioned that a preponderance in any specific gender is unlikely and it develops 7 months to 2 years after the start of SRL (mean SRL levels ranging from 10 to 20 ng/mL) \[[@SFU001C20]\] or a few days to 36 months after the start of EVL (mean EVL levels ranging from 3 to 26 ng/mL) in an arm- or leg-localized lymphoedema form of varying severity (Table [2](#SFU001TB2){ref-type="table"}). Usually, peripheral oedema/lymphoedema was controlled with low doses of furosemide accompanied by reduction of the immunosuppressant \[[@SFU001C43]\]. mTOR-I/PSI-related lymphoedema is not dependent on its cumulative dosage and exposure duration. \[[@SFU001C20]\] Early discontinuation of the drug may prevent permanent disfigurement \[[@SFU001C44]\]. Moreover, the occurrence of limb lymphoedema in renal transplant recipients under SRL treatment, especially if on the same side as the haemodialysis access, should alert the transplant physician to the need for rapid SRL reduction or withdrawal, before complete obstruction occurs, further complicating an already disabling condition. \[[@SFU001C19]\] Close monitoring of this side effect is warranted. Recognizing this association may prevent many unnecessary, costly and invasive investigations. The pathophysiology seems to be due to altered lymphatic drainage \[[@SFU001C18], [@SFU001C19]\]. The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells back into the blood circulation. One pathway of regulation of cell growth and proliferation is mediated by the regulatory associated protein of mTOR (raptor)---G protein β-subunit-like protein (GβL)---and mTOR complex, which is a target of rapamycin. Important downstream effectors of the mTOR system are the translation regulators p70S6 kinase and eukaryotic initiation factor 4E-binding protein \[[@SFU001C45]\]. The mTOR pathway is regulated by the PI3K/AKT kinase system, which is upregulated in tumours. Activation of PI3K/AKT causes activation of mTOR and promotes cell growth and proliferation. Lymphatic endothelium expresses VEGF receptor-3 (VEGFR-3), which is activated after binding to VEGF-C, and VEGF-D plays an important role in lymphangiogenesis. The gene that encodes VEGFR-3 (FLT4) is defective in most families with congenital hereditary lymphoedema \[[@SFU001C46]\] and impaired lymphangiogenesis and lymphoedema is observed in soluble VEGFR-3 (VEGF-C/VEGFD signaling inhibitor) expressing transgenic mice \[[@SFU001C47]\]. Missense mutations of VEGFR-3 prevent normal lymphatic growth in humans \[[@SFU001C46]\]. Huber *et al*. \[[@SFU001C48]\] demonstrate that rapamycin interferes with the intracellular VEGF-C-activated pathway of lymphatic endothelial cells. In rapamycin-treated animals, the anti lymphangiogenic effect during tissue regeneration occurs with prolonged lymphoedema, emphasizing the clinical relevance of this effect of the mTOR inhibition in solid organ transplant recipients.

Effusions {#s5}
=========

An increased incidence of pleural and pericardial effusions has been described in mTOR-I/PSI-treated renal and cardiac transplant patients. The frequency of pericardial effusions following cardiac transplant is 3-fold greater in SRL-treated patients often requiring interventions such as drainage with or without SRL dose reductions \[[@SFU001C49]--[@SFU001C51]\]. The prevalence of effusions, pleural and pericardial, is similar between mycophenolate mofetil-(MMF) and EVL-treated patients, suggesting that this side effect may be PSI specific with greater frequency seen in SRL- versus EVL-treated patients \[[@SFU001C3]\]. Cases of pericardial tamponade have been described following the initiation of SRL both in *de novo* cardiac and late conversion heart transplant patients as well as non-cardiac transplants patients \[[@SFU001C50], [@SFU001C51]\].

Angio-oedema {#s6}
============

AE is a self-limiting swelling that occurs in the deeper cutaneous and mucous membrane layers. Most cases of AE result from a reaction to food or drugs, but some episodes have no identifiable trigger.

Drug-induced AE is well documented in patients taking angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor antagonists (AIIRA), fibrinolytic agents, oestrogens and nonsteroidal anti-inflammatory drugs \[[@SFU001C52]\]. In addition, the frequency of ACEI-induced AE is high in transplant recipients, estimated at ∼1--5 versus 0.1--0.5% in the general population \[[@SFU001C53], [@SFU001C54]\]. Abbosh *et al.* \[[@SFU001C54]\] reported a 24- and 5-fold higher incidence of AE in cardiac and renal transplant recipients, respectively, who were maintained on cyclosporin A, azathioprine and prednisone when compared with the general population. Several reports focused on the putative role of mTOR-I/PSI (SRL and EVL) in the pathogenesis of AE in organ transplant recipients \[[@SFU001C17], [@SFU001C22], [@SFU001C55]--[@SFU001C58]\]. In previous reports, AE associated with SRL occurred in 2.2--15% of patients \[[@SFU001C57], [@SFU001C59]\]. The associated risk factors were ACEI therapy or African-American patients taking metoprolol \[[@SFU001C55], [@SFU001C57]\], which are known to be associated with a higher frequency of AE \[[@SFU001C60]--[@SFU001C62]\]. Fuchs *et al.* \[[@SFU001C17]\] reported that 6 out of their 114 patients (5.3%) experienced for the first time in their lives the occurrence of lingual AE after switching them over to EVL. The time period from starting mTOR-I/PSI to the occurrence of AE ranged from 1 to 41 days. In all six patients, the AE was associated with petechial bleeding and with lingual bullae on the lateral part of the tongue and required hospitalization. At the time when the AE occurred, the following concomitant medications were used: acetyl-salicylic acid (ASS), ACE inhibitors or angiotensin-1-receptor inhibitors. Because the symptoms ceased after discontinuation of ASS in five out of the six patients, it may well be that ASS has triggered the occurrence of EVL-associated side effects. However, the time course after initiation of the immunosuppressive drug, the recurrence in one patient, and the favourable outcome after stopping the drug provide an argument for the pathogenic link between EVL and tongue AE \[[@SFU001C17]\]. Lingual oedema seems to occur predominantly within the first weeks after initiation of mTOR-I/PSI therapy. Drug trough level at presentation is variable within or below the target level or in the toxic range \[[@SFU001C17]\]. A lack of C1-esterase inhibitor could be excluded in all patients. A history of food and/or drug allergies and a lack of C1-esterase inhibitor could be excluded in all patients. In all cases, the condition responded promptly to parenteral steroids, H1 and H2 blockers and discontinuation of SRL. In the majority of patients, the AE seems to disappear without further recurrence after adequate therapy of the symptoms. The responsibility of mTOR-I/PSI in the pathogenesis of AE is suggested either as the sole aetiological factor or more probably as a cofactor \[[@SFU001C17], [@SFU001C22], [@SFU001C56], [@SFU001C57]\] Several hypotheses can be advanced to explain the potential triggering role of mTOR-I/PSI: cytochrome p450 3A4 metabolism pathway interaction \[[@SFU001C63]--[@SFU001C65]\], experimental interaction between mTOR-I/PSI and the bradykinin pathway \[[@SFU001C66]\] and autoimmune diseases induced by mTOR-I/PSI introduction \[[@SFU001C67]\]. The absence of urticaria with AE suggests that mTOR-I/PSI-associated AEs are not IgE mediated \[[@SFU001C17], [@SFU001C22], [@SFU001C56], [@SFU001C57]\].

In conclusion, mTOR-I/PSI may facilitate the occurrence of oedema. This specific adverse event can be easily managed without discontinuation of the drug. It is important to be aware of this phenomenon to avoid burdensome and cost-intense investigations for patients showing this symptom during treatment with mTOR-I/PSI.
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[^1]: MMF, mycophenolate mofetil; TAC, tacrolimus.

[^2]: EVL, everolimus; SRL, sirolimus; TCAV, transplant coronary arterial vasculopathy; NA, not available; LUE, left upper extremity; RUE, right upper extremity; RLE, right lower extremity; CSA, cyclosporine.
